Fmr LLC Lowers Position in Galapagos NV (NASDAQ:GLPG)

Fmr LLC cut its stake in shares of Galapagos NV (NASDAQ:GLPG) by 44.6% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,598,912 shares of the biotechnology company’s stock after selling 1,288,919 shares during the period. Fmr LLC owned 2.43% of Galapagos worth $46,033,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in GLPG. Headlands Technologies LLC grew its position in Galapagos by 56.7% during the second quarter. Headlands Technologies LLC now owns 1,233 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 446 shares during the period. GAMMA Investing LLC lifted its stake in shares of Galapagos by 140.7% in the 3rd quarter. GAMMA Investing LLC now owns 1,259 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 736 shares in the last quarter. Signaturefd LLC grew its holdings in shares of Galapagos by 48.1% during the 2nd quarter. Signaturefd LLC now owns 3,872 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 1,258 shares during the period. China Universal Asset Management Co. Ltd. increased its position in Galapagos by 63.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,899 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 1,510 shares in the last quarter. Finally, Rhumbline Advisers raised its holdings in Galapagos by 21.6% in the second quarter. Rhumbline Advisers now owns 4,578 shares of the biotechnology company’s stock valued at $113,000 after buying an additional 814 shares during the period. 32.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on GLPG. Royal Bank of Canada dropped their price objective on shares of Galapagos from $32.00 to $30.00 and set a “sector perform” rating for the company in a research report on Friday, November 1st. Leerink Partnrs upgraded Galapagos to a “hold” rating in a report on Monday, September 9th. Leerink Partners began coverage on Galapagos in a research note on Monday, September 9th. They set a “market perform” rating and a $24.00 price objective on the stock. Finally, Kepler Capital Markets lowered Galapagos from a “hold” rating to a “reduce” rating in a research note on Wednesday, November 20th. Two research analysts have rated the stock with a sell rating and six have issued a hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $30.75.

Galapagos Trading Up 0.1 %

NASDAQ:GLPG opened at $26.99 on Friday. Galapagos NV has a one year low of $24.16 and a one year high of $42.46. The business’s 50-day simple moving average is $28.17 and its 200 day simple moving average is $27.40.

Galapagos Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.